Drug intelligence / Profile preview

[123I] MNI-308

Development stage
Discontinued
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

The drug name "[123I] MNI-308" does not correspond to a clearly identifiable or widely recognized pharmaceutical compound in publicly available databases. The prefix "[123I]" strongly suggests that it is a radiopharmaceutical, meaning it is a drug labeled with the radioactive isotope Iodine-123. Such compounds are typically used in nuclear medicine for diagnostic imaging, as Iodine-123 emits gamma rays detectable by SPECT (Single-Photon Emission Computed Tomography) scanners. Common examples of Iodine-123 labeled radiopharmaceuticals include Iobenguane I-123 (123I-MIBG), used for imaging neuroendocrine tumors, and Ioflupane I-123 (123I-FP-CIT), used for dopamine transporter imaging in neurological disorders. However, without further context or a direct link in scientific literature or drug databases, the specific chemical identity, mechanism of action, developer, or primary indication of a compound precisely named "MNI-308" labeled with Iodine-123 cannot be determined. It is possible that "MNI-308" is an internal research code, an experimental compound, or a less common designation not widely documented.

02

Targets

DRD1 (Dopamine D1 Receptor)

Beyond the preview

Go deeper on [123I] MNI-308.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [123I] MNI-308.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call